Training improves glaucoma-induced visual field defects

Article

Repetitive activation of residual vision with training of the visual field borders and areas of residual vision can improve visual field defects caused by glaucoma and increase detection sensitivity, according to results from a randomized clinical trial.

Repetitive activation of residual vision with training of the visual field borders and areas of residual vision can improve visual field defects caused by glaucoma and increase detection sensitivity, according to results from a randomized clinical trial published in JAMA Ophthalmology. A new rehabilitation treatment option for such patients may involve behavioural computer-based, online-controlled vision training.

Behavioural vision training has been shown to improve visual fields in hemianopia and optic nerve damage. For this prospective, double-blind, randomized, placebo-controlled clinical trial, researchers gathered a volunteer sample of patients with glaucoma in an ambulatory care and home training setting.

Patients were a mean age of 61.7 years, all with stable visual fields and well-controlled IOPs. Interventions consisted of computer-based vision restoration training for glaucoma (n = 15) or visual discrimination placebo training in the intact visual field (n = 15).

Vision restoration training brought about significant detection accuracy gains in high-resolution perimetry (P = 0.007) not found with white-on-white or blue-on-yellow perimetry. In addition, Pre- to post-differences after training were greater compared with placebo in all perimetry tests (P = 0.02 for high-resolution perimetry; P = 0.04 for both white-on-white and for blue-on-yellow). All results were independent of eye movements.

Vision restoration training for glaucoma but not placebo led to a faster reaction time (P = 0.009). Patients' vision-related quality of life was unaffected, but patients' health-related quality-of-life mental health domain increased in both the vision restoration training and placebo groups.

To view the abstract of this study, click here.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.